Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction

Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials

“…Several meta-analyses [13][14][15][16][17][18][19] confirmed the benefits of gliflozins on CV and/or renal outcomes in HF patients, and moreover, some of them also revealed that these benefits of gliflozins in HF patients were independent of diabetes status, [13][14][15]19] LVEF, [14] and use of ARNI. [18] However, the previous meta-analyses [13][14][15][16][17][18][19] failed to evaluate the impact of most of the factors assessed in the present meta-analysis on the efficacy of gliflozins.…”

“…Several meta-analyses [13][14][15][16][17][18][19] confirmed the benefits of gliflozins on CV and/or renal outcomes in HF patients, and moreover, some of them also revealed that these benefits of gliflozins in HF patients were independent of diabetes status, [13][14][15]19] LVEF, [14] and use of ARNI. [18] However, the previous meta-analyses [13][14][15][16][17][18][19] failed to evaluate the impact of most of the factors assessed in the present meta-analysis on the efficacy of gliflozins. Thus, the findings of this meta-analysis will further inform cardiologists and HF patients that gliflozins are applicable for a broad population of HF patients as for preventing HF events, while gliflozins may lead to greater benefits in patients with mild HF than in those with moderate to severe HF.…”